title: Weak androgen levels, glucocorticoid therapy, and bone mineral density in postmenopausal women with rheumatoid arthritis.
abstract: OBJECTIVE
  To study dehydroepiandrosterone sulfate (DHEAS) and androstenedione (AND) status in postmenopausal women with rheumatoid arthritis (RA), the effects of glucocorticoid therapy on DHEAS and AND levels, and their relationship with bone mineral density (BMD).
  
  
  METHODS
  Forty-six postmenopausal women with RA were separated into two groups based on whether they had a negative history for glucocorticoid therapy (n = 24) or were currently on glucocorticoid therapy (n = 22). The control group was composed of 39 postmenopausal women who had never received hormone replacement therapy. Serum DHEAS and AND levels were measured using a radioimmunoassay. BMD was determined at the lumbar spine (L2-L4) and femoral neck using a DEXA Hologic QDR-1000 densitometer. Results. RA patients and controls were similar in age, weight, body mass index, and years since menopause. DHEAS and AND levels were lower in the glucocorticoid-treated RA group than in the other two groups. The glucocorticoid-treated RA group also had a significantly lower femoral BMD value than the nonglucocorticoid-treated RA group. Lumbar BMD was similar in the two RA groups and in the controls.
  
  
  CONCLUSIONS
  Decreases in DHEAS and AND levels in postmenopausal women with RA are probably related to glucocorticoid therapy rather than to the disease itself.
authors.affiliation: Rheumatology department, Prínceps d'Espanya Hospital, ciutat sanitària i universitària de Bellvitge, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Fiter
authors.forename: J M
authors.initials: JM
authors.lastname: Nolla
authors.forename: M A
authors.initials: MA
authors.lastname: Navarro
authors.forename: C
authors.initials: C
authors.lastname: Gómez-Vaquero
authors.forename: P
authors.initials: P
authors.lastname: Rosel
authors.forename: L
authors.initials: L
authors.lastname: Mateo
authors.forename: D
authors.initials: D
authors.lastname: Roig-Escofet
mesh_terms: D000728:Androgens / Q000097:blood*; D000735:Androstenedione / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000503:physiopathology; D017698:Postmenopause / Q000187:drug effects* / Q000502:physiology*
chemical_list: D000728:Androgens; D005938:Glucocorticoids; D000735:Androstenedione; D019314:Dehydroepiandrosterone Sulfate